ALKBH6

Across TCGA pan-cancer cohorts, ALKBH6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ALKBH6 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ALKBH6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALKBH6 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, PDAC, and LSCC are the cancer types where ALKBH6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.841	0.524	.006	12	view →
PDAC	OS	Median	III,IV	0.416	0.984	.038	3	view →
LSCC	DFS	Quartile	III,IV	1.000	0.717	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ALKBH6–GBM (DFS)

Open the GBM breakdown →